Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma (Nasdaq: CBIO) announced inducement equity option awards approved January 29, 2026, granting an aggregate of 117,339 options to five non-executive employees under the 2025 Employment Inducement Incentive Award Plan.

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) announced inducement equity option awards approved January 29, 2026, granting an aggregate of 117,339 options to five non-executive employees under the 2025 Employment Inducement Incentive Award Plan.

Options have a 10-year term, exercise price of $10.15, and standard four-year vesting with monthly vesting thereafter.

Argus Feb 2 session

+2.40% close to close Open Argus

Details

News Market Reaction – CBIO

On Feb 2, the first trading day after this news, CBIO closed 2.40% above the previous close.

Data tracked by StockTitan Argus for the Feb 2 session.

Market Context

This announcement details standard equity inducement awards totaling 117,339 options to five non-exe...

Analysis

This announcement details standard equity inducement awards totaling 117,339 options to five non-executive employees, with a 10-year term, a $10.15 exercise price, 25% vesting after one year and 1/48th monthly thereafter. It continues Crescent’s recent pattern of option-based hiring incentives alongside earlier strategic and financing developments. Investors may monitor how ongoing pipeline milestones, capital markets activity, and future hiring-related grants collectively shape Crescent’s longer-term execution and equity profile.

Key Figures

Inducement options: 117,339 options Employees granted: 5 employees Exercise price: $10.15 +3 more

Inducement options

117,339 options

Granted to five non-executive employees under 2025 Inducement Plan

Employees granted

5 employees

Recipients of inducement option awards

Exercise price

$10.15

Equal to Nasdaq closing price on January 29, 2026

Option term

10 years

Term of inducement stock options

Initial vesting

25% at 1 year

One-fourth vests on first anniversary of start date

Ongoing vesting

1/48th monthly

Monthly vesting after first anniversary, subject to service

Historical Context

5 past events · Latest: Jan 05

5 events

1. Jan 05

   IND clearances

   24h Move

   +0.3%

   Regulatory clearances for CR-001 and CR-003 and ASCEND trial plans.

2. Dec 18

   Inducement awards

   24h Move

   -3.0%

   Inducement option grants to three non-executive employees.

3. Dec 04

   Partnership & financing

   24h Move

   -4.2%

   Kelun-Biotech partnership plus $185M private placement to fund pipeline.

4. Dec 04

   Strategic partnership

   24h Move

   -4.2%

   Strategic oncology partnership structuring rights and milestones for CR-001, SKB105.

5. Nov 17

   Inducement awards

   24h Move

   -0.5%

   Inducement option grants for eight non-executive employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

equity inducement awards, nasdaq listing rule 5635(c)(4)

2 terms

equity inducement awards financial

"approved the grant of options to purchase an aggregate of 117,339 shares ... as equity inducement awards"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

nasdaq listing rule 5635(c)(4) regulatory

"material to each employee's acceptance of employment ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that its independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 117,339 shares of the Company’s ordinary shares to five non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on January 29, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $10.15, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on January 29, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma 

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. 

Contact

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Crescent Biopharma (CBIO) announce on January 29, 2026 regarding inducement awards?

Crescent Biopharma granted an aggregate of 117,339 stock options to five non-executive employees as inducement awards. According to Crescent Biopharma, the grants were approved January 29, 2026, under its 2025 Inducement Plan and were material to each hire.

What are the key terms of the CBIO inducement options, including price and term?

The options carry a 10-year term and an exercise price of $10.15 per share, equal to the closing price on January 29, 2026. According to Crescent Biopharma, each option is governed by the Inducement Plan and an individual option agreement.

How do the CBIO options vest for the employees who received inducement awards?

Options vest one-fourth on the first anniversary of each employee’s start date and then monthly at one-forty-eighth thereafter. According to Crescent Biopharma, vesting is subject to continuous service through applicable vesting dates.

Why were the stock options granted as inducement awards under Nasdaq rules for CBIO?

The options were granted as inducement awards because they were material to each employee’s acceptance of employment, consistent with Nasdaq Listing Rule 5635(c)(4). According to Crescent Biopharma, the independent Compensation Committee approved the grants.

Will the CBIO inducement option grants immediately dilute existing shareholders?

The grants create potential future dilution only if options are exercised; they do not immediately issue new shares. According to Crescent Biopharma, the options have a ten-year exercise window and are subject to plan terms and exercise events.